NEW YORK, NY / ACCESSWIRE / April 24, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 237.
The investigation concerns whether Globus and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On April 24, 2015, the Company announced in a Securities and Exchange Commission ("SEC") filing that "[o]n April 16, 2015, KPMG LLP ("KPMG") orally notified Globus Medical, Inc. (the "Company") that upon the completion of KPMG's review of the Company's consolidated financial statements for the quarterly reporting period ended March 31, 2015 and the filing of the related Quarterly Report on Form 10-Q, KPMG declines to stand for reelection as the independent registered public accounting firm for the Company. KPMG's decision was accepted by the audit committee of the Company's board of directors."
On this news, shares of Globus fell $0.45 per share, to $24.64, or more than 1.79%, on April 23, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
SOURCE: Pomerantz LLP